| 13 Mars 2018
During 2017, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter -2 (SGLT-2) inhibitors marketed across the seven major markets (7MM*) brought in more than $8bn in combined sales, observes GlobalData, a leading data and analytics company. Both T2D drug classes continue to gain substantial market share through the glycemic and non-glycemic benefits (e.g. CV benefits, weight and/or blood pressure reductions) they confer.
Jesus Cuaron, PhD, PPM, Managing Healthcare Analyst at GlobalData commented: ‘‘Across the 7MM, there are currently fourteen approved GLP-1 receptor agonists and SGLT-2 inhibitors collectively (not including combination varieties). The timeline of approved GLP-1 receptor agonists and SGLT-2 inhibitors in the 7MM, confirms that Novo Nordisk’s Ozempic (semaglutide) and Merck and Pfizer’s Steglatro (ertugliflozin) received the most recent regulatory approvals in 2017. ‘’
IMAGE FOR PUBLICATION. CLICK ON THIS LINK: Timeline of Approved GLP-1 RAs and SGLT-2 Is in the 7MM
Ozempic is a once-weekly injectable GLP-1 receptor agonist drug that has been shown to provide significant reductions of both glycated hemoglobin (A1c) and the risk of major adverse cardiovascular (CV) events, as witnessed in the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6).
Cuaron continued: ‘‘Steglatro, a SGLT-2 inhibitor, provides significant A1c reductions while also harboring numerous non-glycemic advantages, such as weight loss and a reduction in systolic blood pressure. Ozempic and Steglatro are set to launch in the US in 2018, and are expected to gain a significant share of the huge T2D market.’’
Despite the array of drugs currently available for T2D, additional treatments are required for patients to manage the chronic disease. Key Opinion Leaders interviewed by GlobalData agreed that a continued influx of GLP-1 receptor agonists and SGLT-2 inhibitors represent promising additions to existing T2D treatments, as they offer both glycemic and non-glycemic benefits. Post 2017 GLP-1 receptor agonist and SGLT-2 inhibitor contenders include Novo Nordisk’s NN9924, an oral version of Ozempic, Sanofi’s sotagliflozin, a dual SGLT-1 and SGLT-2 inhibitor, and Theracos’ bexagliflozin, a novel SGLT-2 inhibitor.
Cuaron added, ‘‘As such, we believe the GLP-1 receptor agonists and SGLT-2 inhibitors will experience the fastest growth of any T2D drug class.’’
* 7MM: USA, 5EU (France, Italy, Germany, Spain, UK), and Japan
